Kedrion IVIG 10% not checked
Kedrion S.p.A. · KIg10 · Immune globulin 10%
FollowEvery change as it happens, and a Monday email
Trials
4 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Immunodeficiency Disease, Chronic Primary Immune Thrombocytopenia (ITP), Chronic Inflammatory Demyelinating Polyneuropathy, Stiff Person Syndrome
- Main trialPhase 3
- “The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).”In the company’s words, NCT04944979 on ClinicalTrials.gov
- Other names
- KIg10 · QIVIGY · Immune globulin 10%
Other drugs for Primary Immunodeficiency Disease
- PanzygaOctapharma · Phase 3
- IVIG-VImmuneVirchow Group · Phase 3
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
- ADX-324ADARx Pharmaceuticals, Inc. · Phase 3
Coming up4
- DecPhase 3 trial completes · ClinicalTrials.gov
- DecPhase 3 trial completes · ClinicalTrials.gov
- 20 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | |
| Phase 3Recruiting | Dec 2026 | A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | |
| Phase 3Recruiting | 20 Dec 2027 | A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |
| Phase 3Not yet recruiting | Jan 2028 | A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome | |
| Phase 3Completed | 27 Aug 2014 | Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) | |
| Phase 3Completed | 21 Dec 2020 | Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026